Código QR (código de barras bidimensional)

Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trialResearch in context

Summary: Background: Type 2 diabetes (T2DM) remains a challenge to treat despite the expansion of various therapeutic classes. Visepegenatide (PB-119) is a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection without the requirement of dose titration that has sho...

ver descrição completa

Na minha lista:
Principais autores: Xiang Yan, Jianhua Ma, Yan Liu, Xuhong Wang, Sheli Li, Shuang Yan, Zhaohui Mo, Yikun Zhu, Jingna Lin, Jie Liu, Ying Jia, Li Liu, Ke Ding, Michael Xu, Zhiguang Zhou
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2024-06-01
coleção:The Lancet Regional Health. Western Pacific
Assuntos:
Visepegenatide
HbA1c
Glycaemic control
Diabetes
BMI
GLP-1 RA
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666606524000956
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados